CCL5 and liver dysplastic nodule: In a mouse model of advanced DN, administration of the TLR4 antagonist CRX526 significantly decreased albuminuria, blood urea nitrogen, glomerular hypertrophy, glomerulosclerosis and tubulointerstitial injury, an effect related to the impairment in CCL2/CCL5 levels, TGFβ and NF-κB activity [232].